Abstract
Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 258-271 |
| Number of pages | 14 |
| Journal | Advanced Drug Delivery Reviews |
| Volume | 62 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 17 2010 |
Fingerprint
Keywords
- Arthritis
- Bone-targeting
- Central nervous system (CNS)
- HPMA copolymers
- Infectious diseases
- Musculoskeletal diseases
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Beyond oncology - Application of HPMA copolymers in non-cancerous diseases. / Liu, Xin Ming; Miller, Scott C.; Wang, Dong.
In: Advanced Drug Delivery Reviews, Vol. 62, No. 2, 17.02.2010, p. 258-271.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Beyond oncology - Application of HPMA copolymers in non-cancerous diseases
AU - Liu, Xin Ming
AU - Miller, Scott C.
AU - Wang, Dong
PY - 2010/2/17
Y1 - 2010/2/17
N2 - Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.
AB - Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.
KW - Arthritis
KW - Bone-targeting
KW - Central nervous system (CNS)
KW - HPMA copolymers
KW - Infectious diseases
KW - Musculoskeletal diseases
UR - http://www.scopus.com/inward/record.url?scp=75749129808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75749129808&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2009.10.006
DO - 10.1016/j.addr.2009.10.006
M3 - Review article
VL - 62
SP - 258
EP - 271
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
IS - 2
ER -